810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
id |
doaj-00623983293a4f6b8c5349d69879b125 |
---|---|
record_format |
Article |
spelling |
doaj-00623983293a4f6b8c5349d69879b1252020-12-11T10:04:07ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0810810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumorsDan Liu0Jing Yang1Lin Shen2Yue Yang3Ting Xu4Jifang Gong5Zhi Dong6June Xu7Yakun Qi8Jie Men9Paul Kong101Beijing Cancer Hospital, Beijing, China2Jiangsu Alphamab Biopharmaceuticals Co., suzhou, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China2Jiangsu Alphamab Biopharmaceuticals Co., suzhou, China2Jiangsu Alphamab Biopharmaceuticals Co., suzhou, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China1Beijing Cancer Hospital, Beijing, China2Jiangsu Alphamab Biopharmaceuticals Co., suzhou, China2Jiangsu Alphamab Biopharmaceuticals Co., suzhou, China2Jiangsu Alphamab Biopharmaceuticals Co., suzhou, China2Jiangsu Alphamab Biopharmaceuticals Co., suzhou, China |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Dan Liu Jing Yang Lin Shen Yue Yang Ting Xu Jifang Gong Zhi Dong June Xu Yakun Qi Jie Men Paul Kong |
spellingShingle |
Dan Liu Jing Yang Lin Shen Yue Yang Ting Xu Jifang Gong Zhi Dong June Xu Yakun Qi Jie Men Paul Kong 810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors Journal for ImmunoTherapy of Cancer |
author_facet |
Dan Liu Jing Yang Lin Shen Yue Yang Ting Xu Jifang Gong Zhi Dong June Xu Yakun Qi Jie Men Paul Kong |
author_sort |
Dan Liu |
title |
810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors |
title_short |
810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors |
title_full |
810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors |
title_fullStr |
810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors |
title_full_unstemmed |
810 Preliminary safety, tolerability and efficacy results of KN026 in combination with KN046 in patients with HER2 aberrated solid tumors |
title_sort |
810 preliminary safety, tolerability and efficacy results of kn026 in combination with kn046 in patients with her2 aberrated solid tumors |
publisher |
BMJ Publishing Group |
series |
Journal for ImmunoTherapy of Cancer |
issn |
2051-1426 |
publishDate |
2020-11-01 |
work_keys_str_mv |
AT danliu 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors AT jingyang 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors AT linshen 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors AT yueyang 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors AT tingxu 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors AT jifanggong 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors AT zhidong 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors AT junexu 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors AT yakunqi 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors AT jiemen 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors AT paulkong 810preliminarysafetytolerabilityandefficacyresultsofkn026incombinationwithkn046inpatientswithher2aberratedsolidtumors |
_version_ |
1724386412540723200 |